



FOR IMMEDIATE RELEASE

Anagram Therapeutics Appoints Three Industry Veterans to Leadership Team, Focused on Accelerating the Company's Pipeline of Orally Delivered Enzymes for Rare Diseases

FRAMINGHAM, Mass., April 20, 2023 - [Anagram Therapeutics Inc.](#), a clinical-stage biopharmaceutical company dedicated to improving the lives of people with cystic fibrosis (CF) and other rare diseases, today announced the appointment of three new members to its executive leadership team. Effective immediately, Hugh Wight will serve as chief, corporate development, Pamela Nelson as executive vice president, regulatory affairs, and Sophia Sassoon as vice president, quality.

"Hugh, Pam and Sophia are important additions to the Anagram leadership team, bringing extensive biopharmaceutical experience and expertise in their respective fields," said Robert Gallotto, president and chief executive officer of Anagram Therapeutics. "As we plan for several significant near-term milestones and transition to a clinical-stage development company with a deep pipeline of assets, their industry knowledge and background in bringing products from development to the market will position us for continued growth and success."

Anagram will advance a pipeline of orally delivered enzymes targeting malabsorption syndromes and nutrient metabolism disorders. The company's lead product, ANG003, is entering clinical trials in people with CF for the treatment of malabsorption and exocrine pancreatic insufficiency. Earlier this month, Anagram announced that the Cystic Fibrosis Foundation recently agreed to provide additional funding to support clinical development of ANG003, up to approximately \$35 million.

Hugh Wight, Anagram's chief, corporate development, has over 30 years of experience in the pharmaceutical and biotech industries, including various executive leadership roles in strategic portfolio planning in rare disease and with orally delivered enzymes. Mr. Wight had program management responsibility for the development of proteins and small molecules, from the pre-investigational stage to marketing authorization. At Anagram, Mr. Wight will work with internal stakeholders, external collaborators, and business development partners to advance the company's pipeline of assets. Prior to joining Anagram, Mr. Wight served as senior vice president, technical operations at Allena Pharmaceuticals and had successful engagements with Alnara Pharmaceuticals, Altus Pharmaceuticals and Alkermes.

Pamela Nelson, Anagram's executive vice president, regulatory affairs, has more than 25 years of biotechnology experience across a spectrum of roles in regulatory affairs, providing strategic oversight for the advancement of multiple pipeline programs and the associated interactions with federal agencies. Ms. Nelson has led global regulatory strategies for all phases of development through commercialization, across a range of therapeutic areas, including extensive experience in rare diseases, orally delivered enzymes and product launches. Most recently she served as senior vice president, regulatory affairs at Lyra Therapeutics. Previously, Ms. Nelson held regulatory positions at Avedro, Alnara Pharmaceuticals, Altus Pharmaceuticals, Alkermes and Genzyme.

-- more --

Sophia Sassoon, Anagram’s vice-president, quality is an experienced executive in the biopharmaceutical industry, including senior leadership roles in both quality and compliance. Ms. Sassoon has significant experience providing strategic and operations leadership including oversight for nonclinical and clinical programs throughout the entire product lifecycle. Ms. Sassoon has been responsible for developing and implementing global systems and processes while assuring compliance and strategic risk mitigation across both development and commercial products. Prior to joining Anagram, Ms. Sassoon served as the senior director of quality at 89bio and held quality positions at RedHill Biopharma, Humacyte, and Grifols.

“We are extremely pleased to welcome these industry veterans as we leverage our science and build important collaborations to bring new treatments to people with cystic fibrosis and other rare diseases,” added Gallotto. “As a leadership team we are focused on executing our mission to become the world’s leading biopharmaceutical company developing breakthrough treatments for malabsorption syndromes and nutrient metabolism disorders.”

Malabsorption syndromes and nutrient metabolism disorders are a group of conditions caused by enzyme deficiencies or genetic disorders that prevent the body from properly processing or absorbing certain fats, sugars, proteins, vitamins or other key nutrients. Anagram aims to create a new class of orally delivered enzyme replacement therapy (ERT) based on a deep knowledge of gastrointestinal disease pathology, advances in enzyme engineering and formulation technologies, with an experienced team that has previously built successful enzyme-based biotech companies. The company’s lead product, ANG003, delivers a broad-spectrum ERT (i.e., lipase for fat, protease for protein, and amylase for carbohydrate), targeting some of the most challenging diseases in infants, children and adults. In addition to ANG003 the company plans to advance three pipeline candidates targeting carbohydrate malabsorption disorders.

About Anagram Therapeutics

Anagram Therapeutics Inc. is a clinical stage biopharmaceutical company developing novel, orally delivered enzyme therapeutics for the treatment of serious diseases caused by malabsorption syndromes and nutrient metabolism disorders that prevent the body from properly processing or absorbing certain fats, sugars, proteins, vitamins or other key nutrients. The company is leveraging proprietary enzyme technologies and expertise in gastrointestinal diseases to solve complex problems and advance a pipeline of products that can make a life-changing impact for people and their families living with cystic fibrosis and other rare diseases. ANG003, Anagram’s lead product for the treatment of malabsorption and exocrine pancreatic insufficiency, is a new class of broad-spectrum digestive enzyme replacement therapy entering clinical trials in people with cystic fibrosis. Anagram is a privately held company headquartered in Framingham, MA. To learn more, visit www.anagramtx.com or follow us on [LinkedIn](#) and [Twitter](#).

#

Company Contact:

Kathryn Kilroy
Anagram Therapeutics
kkilroy@anagramtx.com
(617) 466-3823

Media Contact:

Gina Cella
Cella Communications
gcella@cellapr.com
(781) 799-3137 (mobile)